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Abstract
Background: Physical activity is associated with a reduced risk of type 2 diabetes and cardiovascular disease but
limited evidence exists for the sustained promotion of increased physical activity within diabetes prevention trials.
The aim of the study was to investigate the long-term effectiveness of the Walking Away programme, an
established group-based behavioural physical activity intervention with pedometer use, when delivered alone or
with a supporting mHealth intervention.
Methods: Those at risk of diabetes (nondiabetic hyperglycaemia) were recruited from primary care, 2013–2015, and
randomised to (1) Control (information leaflet); (2) Walking Away (WA), a structured group education session
followed by annual group-based support; or (3) Walking Away Plus (WAP), comprising WA annual group-based
support and an mHealth intervention delivering tailored text messages supported by telephone calls. Follow-up
was conducted at 12 and 48 months. The primary outcome was accelerometer measured ambulatory activity
(steps/day). Change in primary outcome was analysed using analysis of covariance with adjustment for baseline,
randomisation and stratification variables.
Results: One thousand three hundred sixty-six individuals were randomised (median age = 61 years, ambulatory
activity = 6638 steps/day, women = 49%, ethnic minorities = 28%). Accelerometer data were available for 1017
(74%) individuals at 12 months and 993 (73%) at 48 months. At 12 months, WAP increased their ambulatory activity
by 547 (97.5% CI 211, 882) steps/day compared to control and were 1.61 (97.5% CI 1.05, 2.45) times more likely to
achieve 150 min/week of moderate-to-vigorous physical activity. Differences were not maintained at 48 months. WA
was no different to control at 12 or 48 months. Secondary anthropometric and health outcomes were largely
unaltered in both intervention groups apart from small reductions in body weight in WA (~ 1 kg) at 12- and 48-
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month follow-up.
Conclusions: Combining a pragmatic group-based intervention with text messaging and telephone support
resulted in modest changes to physical activity at 12 months, but changes were not maintained at 48 months.
Trial registration: ISRCTN 83465245 (registered on 14 June 2012).
Keywords: Diabetes prevention, mHealth, Randomised controlled trial, Non-diabetic hyperglycaemia, Group-based
intervention, Physical activity, Pedometer
Background
The rising burden of type 2 diabetes (T2D) has precipi-
tated three decades of research and healthcare policies
concerning prevention among individuals deemed to be
at risk. Large trials have demonstrated that intensive life-
style interventions targeting diet, physical activity and
weight loss reduce the risk of developing T2D by 50%
[1]. Translational research has demonstrated that life-
style diabetes prevention programmes also lead to mod-
est weight loss when implemented within routine
clinical settings [2]. This has led to commissioning and
delivery of lifestyle advice and diabetes prevention pro-
grammes within routine health care settings [3, 4].
Whilst the intensive interventions in the seminal dia-
betes prevention trials achieved initial weight loss, there is
little evidence of sustained increases in physical activity
over the longer term (> 12months) [5]. This is important
as even modest increases in physical activity decrease the
risk of cardiovascular disease and improve glycaemic con-
trol independently of changes in weight in high risk
groups [6, 7] and facilitate maintenance of weight loss.
Furthermore, uptake of and retention in real-world dia-
betes prevention programmes is sub-optimal [3, 4], sug-
gesting alternative strategies are required.
The Walking Away from type 2 diabetes programme
(referred to hereinafter as “Walking Away”) is a 3-h
group-based structured education programme with an-
nual refresher sessions that was developed for imple-
mentation within family practice and has been widely
commissioned into routine care [8]. An early trial dem-
onstrated small changes in physical activity over 12
months, but with evidence of greater behaviour change
in those with nondiabetic hyperglycaemia [8].
The PROPELS trial investigated the longer-term ef-
fectiveness of Walking Away in a multi-ethnic popula-
tion with nondiabetic hyperglycaemia, when delivered in
a standard format or when integrated with a bespoke
mHealth intervention designed to maintain physical ac-
tivity behaviour change.
Methods
The PRomotion Of Physical activity through structured
Education with differing Levels of ongoing Support for
those with prediabetes (PROPELS) study is a multi-
centre, open, individually randomised three-arm trial,
described in the published protocol [9]. Ethical approval
was granted by the NHS National Research Ethics Ser-
vice, East-Midlands Leicester Committee (Ethics num-
ber: 12/EM/0151). Participant recruitment commenced
in December 2013 and was completed in February 2015,
with follow-up data collection completed in July 2019.
Recruitment of participants
Participants were recruited from the East Midlands and
Eastern regions of England, purposefully targeting areas
with large multi-ethnic communities. The primary
method of recruitment was through family practice, sup-
plemented by recruitment from research databases.
Age eligibility was 40 to 74 years for White Europeans,
or 25–74 years for those from an ethnic minority to ac-
count for higher diabetes risk status and to comply with
national guidelines [10]. Additional eligibility criteria
were previously recorded plasma glucose or HbA1c value
in the nondiabetic hyperglycaemia range (HbA1c ≥ 42
[6.0], < 48 [6.5] mmol/mol [%]; fasting glucose ≥ 5.5, <
7.0 mmol/l; 2-h post-challenge glucose ≥ 7.8, < 11.1
mmol/l) within the last 5 years, and access to a mobile
phone. Individuals unable to take part in ambulatory-
based activity, were pregnant, diagnosed with diabetes or
non-English speakers were excluded.
Randomisation and blinding
Participants were randomised (stratified by centre [Leices-
ter vs. Cambridge], sex and ethnicity [White European vs.
other]) using an online randomisation tool (https://www.
sealedenvelope.com/) through the University of Leicester
Clinical Trials Unit. Individuals were randomised (1:1:1)
to one of three groups: Control, Walking Away (WA) or
Walking Away Plus (WAP). Allocation was not blinded
due to the nature of the trial. However, study allocation
was concealed from the study measurement and labora-
tory teams and the research staff processing the acceler-
ometer data (primary outcome).
Control
Participants allocated to control received an advice leaf-
let targeting knowledge of nondiabetic hyperglycaemia
and highlighting the importance of physical activity.
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Walking Away (WA)
WA is a 3-h group-based, theory-driven, behavioural
intervention addressing knowledge and perceptions of
diabetes risk and promoting increased physical activity;
the theoretical underpinning, content and structure of
the intervention has been described previously [9]. The
central aim is to promote increases of physical activity
up to 3000 steps/day. Goal attainment is encouraged
through the provision of pedometers (Yamax SW200)
and step/day dairies. A short section of the curriculum is
also allocated to covering key dietary messages.
WA sessions were delivered by two trained educators
following a structured curriculum to groups of up 10
participants. Sessions were delivered in a variety of set-
tings chosen for proximity to recruiting family practices,
including the practices themselves, in nearby community
centres or at hospital sites.
Participants were offered annual group-based follow-
on maintenance sessions at 12, 24 and 36months. An-
nual follow-on sessions lasted 2.5 h and were designed
to revisit the key messages of the initial session,
strengthen self-efficacy through sharing successes and
prompt problem-solving in relation to barriers, goal set-
ting and pedometer use.
Walking Away Plus (WAP)
Participants assigned to WAP were invited to attend the
same WA session and annual refresher sessions as de-
scribed above [9, 11]. In addition, they received an
mHealth follow-on support intervention which was
based on prompting participants by text to set goals and
to text back step counts. Automated feedback was then
texted to participants with the content tailored to suc-
cess with achieving goals and other individual tailoring
characteristics such as self-efficacy that were captured
during an initial telephone call with trained staff within
a week of attending WA. The content of the automated
text messages were developed for use with Walking
Away, as described previously [9, 11]. Text messages
were sent at least weekly over the first 6 months and
then monthly. Participants could opt out of receiving
texts. Participants also received a further telephone call
at six months to review progress. The telephone call and
text message frequency was repeated after each annual
group-based follow-on session [9].
Primary outcome measure
The primary outcome was change in ambulatory activity
(steps/day) at 48 months, assessed by accelerometer
(Actigraph GT3X+), with an intermediary assessment at
12 months. Participants were asked to wear the acceler-
ometer on a waistband (on the right anterior axillary
line) during waking hours for seven consecutive days.
Acceleration data were integrated into 60-s epochs. At
least 3 days valid wear (≥ 10 h of data per day) were re-
quired for inclusion in the analysis. Non-wear time was
determined by one hour or more of consecutive zero
counts.
Actigraph accelerometers have previously been shown
to produce valid measures of steps taken during tread-
mill and free-living walking [12, 13], particularly for
moderate and brisk stepping where intraclass correlation
coefficients compared to criterion measures have been
shown to be > 0.9.
Secondary outcomes
The accelerometer used to measure the primary out-
come also measured censored ambulatory activity, de-
fined as steps taken above an intensity (500 counts/
minute) distinguishing between purposeful and inciden-
tal ambulation [14]. Freedson cut-points distinguished
between time spent sedentary, in light-intensity physical
activity and in moderate-to-vigorous intensity physical
activity (MVPA) [15]. Compliance with physical activity
recommendations (undertaking at least 150 min of
MVPA per week) was also assessed as total MVPA or
that undertaken in at least 10-min bouts.
Participants were also asked to wear an activPAL3™
device, attached to the thigh to determine time spent sit-
ting, standing and stepping. Data were analysed using an
open-source processing package (ProcessingPAL, Uni-
versity of Leicester https://github.com/UOL-COLS/
ProcessingPAL).
Self-reported physical activity energy expenditure was
measured using the validated recent physical activity
questionnaire [16]. Sleep duration was assessed by self-
report (last night and average duration) [9]. HbA1c, lipid
profile (triglycerides, HDL, LDL, total cholesterol), urea
and electrolytes (sodium, potassium, urea, creatinine)
and liver function tests (albumin, total bilirubin, alkaline
phosphatase, alanine transaminase) were assessed using
venous samples. During the course of the trial, those
found to have diabetes (HbA1c ≥ 6.5% or 48mmol/mol)
continued to be offered all study and interventional
procedures.
Information on ethnicity was obtained by self-report.
We calculated modelled cardiovascular risk using the
Framingham Risk Score. Social deprivation was assessed
using the Index of Multiple Deprivation (IMD) score de-
rived for each participant’s postcode.
Dietary behaviour was measured by an abbreviated
food frequency questionnaire developed for the Euro-
pean Prospective Investigation of Cancer and Nutrition
(EPIC) study and a questionnaire of dietary intentions
developed for the NAVIGATOR (Nateglinide And Val-
sartan in Impaired Glucose Tolerance Outcomes Re-
search) study [17, 18].
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We measured health-related quality of life using the
European Quality of Life-5 Dimensions (EQ-5D-5L) and
the Short Form (SF-8). Depression and anxiety were
assessed using the Hospital Anxiety and Depression
Scale (HADS) [9], medical history and medication status
by interview administered protocol and family history of
diabetes and cardiovascular disease, smoking status and
muscular/skeletal injury were assessed by self-report. All
adverse events reported to the study sponsor (University
of Leicester) were recorded.
Family practice data
We collected data on biochemistry, diabetes diagnosis
and other medical events that occurred during the trial
directly from consenting participants’ family practice re-
cords for those lost to follow-up.
Mediators of behaviour change
The Brief Illness Perceptions Questionnaire (BIPQ) was
used to measure perceptions and perceived knowledge
of diabetes risk [9]. Participants’ confidence in their abil-
ity to walk for 10, 30 and 60 min each day was assessed
using rating scales (ranging from 0% [no confidence] to
100 % [complete confidence]) [9]. The use of behaviour
change strategies at 12 and 48 months were assessed
using a 5-point Likert scale. Items assessed included
how often participants set goals, formed action plans,
used a pedometer, completed a physical activity log,
were aware of their activity levels and were trying to be
more physically active [9].
Sample size
Assuming a 2.5% significance level (allowing for two a
priori comparisons of WA and WAP against control)
and 80% power, based on an SD of 4000 steps/day over
4 years [9], 918 participants (306 per group) were re-
quired to complete the trial in order to detect a 1000
steps/day difference in change in ambulatory activity.
Allowing for 30% loss to follow-up or incomplete pri-
mary outcome data, the recruitment target was 1308.
Statistical analysis
The statistical analysis plan was published on the trial
registry (ISRCTN 83465245) before unblinding of data.
We compared change in the primary outcome between
each intervention group and the control group using
analysis of covariance (ANCOVA) with adjustment for
baseline, randomisation stratification variables (centre,
ethnicity, sex). Accelerometer outcomes were also ad-
justed for wear time at baseline and follow-up, and num-
ber of valid days of wear at baseline and follow-up. Data
on illness perception, self-efficacy and self-reported use
of behaviour change strategies were summarised
descriptively.
In order to investigate the potential impact of missing
data, further analyses of the primary outcome were per-
formed using multiple imputation by chained equations
(also assuming MAR), and a pattern mixture model, to
investigate departures from the MAR assumption [19].
For the primary outcome, pre-specified interactions
between randomised group and the following baseline
variables were investigated: ethnicity (White European/
South Asian/Other), sex (men/women), age (< 60 years/≥
60 years), family history of T2D (yes/no), nondiabetic
hyperglycaemia (yes/no), obesity status (< 30 kg/m2
[27.5 kg/m2 for South Asians], ≥ 30 kg/m2 [27.5 kg/m2
for South Asians]) and deprivation (split at median IMD
score into high vs low).
A per-protocol analysis was conducted according to
the following criteria:
Control – all individuals.
WA – attended initial session AND at least 1 follow-
up annual refresher session.
WAP – attended initial session AND at least 1 follow-
up annual refresher session AND registered with the text
service AND received the initial telephone call AND re-
ceived at least one further telephone call during the trial.
Significance was set at p < 0.025 for main effects with
results reported as mean (97.5% CI) to account for mul-
tiple testing and P < 0.05 for interactions. Analyses were
performed using Stata version 15.1 (StataCorp 2017)
Results
Invitation letters were sent to 12,417 individuals from 47
different family practices, with a further 746 invited from
previous research databases. Of these, 1563 individuals
provided consent and were screened, with 1366 meeting
the inclusion criteria and randomised. The flow of par-
ticipants is shown in Fig. 1. The sociodemographic and
clinical characteristics of participants, stratified by ran-
domised group, are presented in Table 1; 28% were from
black and minority ethnic populations. Primary outcome
data at 48-month follow-up were available for 993
(72.7%). The characteristics of those with and without
primary outcome data, stratified by intervention group,
are shown in Additional File 1.
Intervention engagement and adherence
Intervention engagement for each intervention group is
shown in Table 2. Approximately 80% attended the ini-
tial WA session in both groups, and over two thirds
attended at least one annual group-based follow-on ses-
sion. There was also reasonable engagement with the
key elements of the mHealth intervention in WAP (Add-
itional file 2). At 48 months, 64.2% in WAP and 49.7% in
WA still reported using their pedometer at least some of
the time. Similarly, 40.9% and 30.6% in WAP and WA
respectively reported keeping a physical activity log at
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least some of the time, compared to 11.1% in the control
group. Self-efficacy for walking was high at baseline in
all groups and remained high throughout the trial (Add-
itional file 3). Illness perception scores indicated WA
and WAP increased perceived understanding of diabetes
risk over the course of the trial, whereas understanding
remained stable in the control group (Additional file 3).
Primary outcome
Total ambulatory activity (primary outcome) and phys-
ical variables at baseline and subsequent 12- and 48-
month change values are presented in Table 3 and Fig. 2.
At baseline, the control, WA and WAP groups took an
average (SD) of 6885 (3068), 7264 (3009) and 7353
(3432) steps/day, respectively. WAP increased total
ambulatory activity at 12 months by 547 (97.5% CI 211,
882) steps/day relative to control (Fig. 2). The results for
total ambulatory activity were consistent with those for
censored ambulatory activity (Fig. 2), indicating the in-
crease was due to purposeful movement. No change in
either group was found at 48 months compared to con-
trol (WA vs control 91 [− 282, 463] steps/day, WAP vs
control 121 [− 290, 532] steps/day).
At 48 months, 278 (62%) in WA and 235 (52%) in
WAP met the per-protocol definition; results were simi-
lar when analyses were restricted to this population
(Additional file 4). Results for the primary outcome were
also comparable following multiple imputation (Add-
itional file 4), with the pattern mixture model showing
similar conclusions even when there were substantial
Fig. 1 Participant flow
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deviations from the MAR assumption. Furthermore, the
results were consistent across sex, age, ethnicity, family
history of diabetes and baseline prediabetes and obesity
status (Additional file 5). However, there was evidence
that the primary outcome was modified by social
deprivation (p = 0.035 for interaction); in WAP com-
pared to the control group, those below the median level
of social deprivation had a decrease in activity level at
48 months (− 370 (− 945, 205) steps/day), whilst those
above the median increased their ambulatory activity
(480 (− 73, 1033) steps/day) (Additional file 5).
Physical activity and sedentary behaviour
Time in MVPA increased by 3.5 (0.6, 6.5) min/day and
time spent walking increased by 8.5 (3.3, 13.7) min/day
in WAP compared to control at 12 months, but differ-
ences were not sustained at 48 months (Table 3). There
were no differences between either intervention group
compared to control in time spent in measures of seden-
tary behaviour, standing or in light-intensity physical ac-
tivity (Table 3).
The odds of meeting the physical activity guidelines at
12 months was 1.61 [1.05, 2.45] times higher in WAP
compared to control with similar results when consider-
ing time accumulated in at least 10-min bouts (OR =
1.63; 1.04, 2.55). However, no differences were observed
at 48 months.
There was an increase in total self-reported physical
activity energy expenditure in WAP compared to the
control of 4.4 (0.0, 8.8) kJ/kg/day at 48 months (Add-
itional file 6).
Other secondary outcomes
Baseline values and the intervention effect at 12 and 48
months for all secondary outcomes are reported in Add-
itional file 6. At 48 months in WA, there was a 1.00
(0.07, 1.92)kg reduction in body mass, a 1.57 (0.45,
2.70)cm reduction in waist circumference and a 1.06
(0.33, 1.79)% reduction in body fat percentage compared
to control, with changes also observed at 12 months.
Apart from a small decrease in triglycerides (− 0.15
mmol/l; − 0.29, − 0.01) in WAP at 48 months and a re-
duction in liver enzymes alanine aminotransferase (ALT)
and alkaline phosphatase (ALP) in WA, there was no
other clear pattern of differences between groups in clin-
ical outcomes, depression or quality of life.
Both intervention groups reported increases in fresh
fruit and vegetable consumption over the course of the
trial; however, differences were small with increases of
less than one portion a week compared to control (Add-
itional file 6).
During the trial, 39 (9.3%) individuals in control, 30
(7.8%) individuals in WA and 41 (10.4%) individuals in
WAP developed T2D with no difference in either inter-
vention group compared to control.
The number of serious and non-serious adverse events
in the control group was 7 (1.5%) and 47 (3.4%),
Table 1 Sociodemographic and clinical characteristics of









Continuous variables Mean SD Mean SD Mean SD
Age (yrs) 59.4 8.8 59.4 9.4 59.3 9.1
BMI (kg/m2) 28.5 5.7 28.2 5.6 28.4 5.6
Social deprivation (IMD decile) 5.5 2.8 5.7 3.0 5.7 2.8
HbA1c (mmol/mol) 5.8 0.3 5.9 0.4 5.9 0.3
HbA1c (%) 40.0 3.7 40.5 3.5 40.4 3.5
Categorical variables % n % n % n
Sex
Men 50.9 234 50.4 227 50.9 232
Women 49.1 226 49.6 223 49.1 224
Ethnicity
White European 71.1 327 72.4 326 72.1 329
South Asian 22.4 103 22.0 99 22.6 103
Other 6.5 30 5.6 25 5.3 24
Family history of diabetes in
first-degree relatives
43.3 198 42.0 188 45.3 205
Antihypertensive medication 40.9 169 44.6 164 44.7 170
Lipid-lowering medication 34.9 144 37.2 137 39.6 150
Steroids 7.4 34 9.1 41 6.4 29
Metformin 0.0 0 0.2 1 0.2 1
CVD (MI, heart failure, angina,
stroke)
8.6 39 9.0 40 9.9 45
Smoking status
Past 38.3 176 36.2 163 38.2 174
Current 9.8 45 8.4 38 11.4 52
Employment type
Full time 37.6 173 34.2 154 37.1 169
Part time 16.1 74 20.4 92 18.9 86
Retired 35.0 161 35.3 159 33.6 153
Unemployed or other 11.3 52 10.0 45 10.5 48
Educational status
Degree, higher degree or
equivalent
45.7 205 45.5 197 44.9 202
Marital status
Married/civil partner 68.3 314 75.6 340 73.9 337
Access to the internet 83.0 380 86.2 387 85.3 388
Meeting physical activity
recommendations




21.9 97 25.9 113 24.6 109
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respectively. Equivalent values for WA were 15 (3.3%)
and 14 (3.11%), respectively, and for WAP 28 (6.4%) and
16 (3.5%), respectively. A breakdown of adverse event
reporting in each group is displayed in Additional file 7.
Discussion
Among people with previous nondiabetic hypergly-
caemia, a pragmatic, 3-h group-based behavioural inter-
vention, when combined with tailored text messages and
telephone calls, increased ambulatory activity by over
500 steps/day or 8.5 min/day of walking after the first
12 months; however, effects were not maintained after
48 months. Results were similar in White European and
Black and minority ethnic populations, although there
was evidence that the most socially deprived were least
likely to benefit.
The increase in ambulatory activity seen in the WAP
group relative to control at 12 months, although modest,
is likely to be clinically meaningful [20–22]. Although
evidence from physical activity trials over 12 months is
limited, the finding that such effects are difficult to
maintain over the longer-term is largely consistent with
several smaller trials published whilst PROPELS was on-
going. A physician-led physical activity intervention in
200 participants with established T2D reported a 6.8-
min/day increase in moderate-to-vigorous physical activ-
ity after 12 months, but with effects reducing to 3.6 min
after 36 months [23]; however, unlike PROPELS, there
was evidence of sustained changes to auxiliary behav-
iours such as reductions to sedentary time and increases
in light-intensity physical activity. The PACE-UP ped-
ometer intervention for inactive adults demonstrated in-
creases in ambulatory activity of between 600 and 700
steps/day over 36 months, but the effect for ambulatory
activity was not sustained in 298 older adults aged 60–
75 years over 48 months with differences in MVPA com-
pared to control diminishing to 4.6 min/day [24]. The
LookAHEAD lifestyle intervention for those with T2D
reported that those in the intensive lifestyle intervention
increased their MVPA by 8.3 min/day compared to base-
line after 12 months, with the effect reducing to 1.9 min/
day after 48 months [25]. Taken together, these results
suggest that small, but nevertheless, potentially clinically
meaningful, increases in physical activity are possible
after receiving a behavioural intervention designed for
inactive adults or those with metabolic dysfunction
within family practice, but that such changes may be dif-
ficult for individuals to maintain into the longer-term.
Longer-term physical activity and lifestyle intervention
to date for the prevention and management of T2D have
been based on individual-level behavioural interventions.
However, factors like material and social deprivation and
their impact on the physical environment are major de-
terminants of health and health behaviour [26], includ-
ing physical activity [27]. Therefore, it is possible that
individual-level interventions may fail over the longer-
term where the underlying socioeconomic determinants
of physical inactive remain unchanged.
Although no longer-term changes in physical activity
were reported, the Walking Away group lost weight and
reduced their waist circumference by 1 kg and 1.6 cm
compared to control at 48 months. Although sustained,
these changes were relatively modest with smaller effects
than interventions that are specifically aimed at long-
term weight loss [28]. Whilst the impact of this degree
of weight loss on mortality outcomes is uncertain [28],
the Diabetes Prevention Program reported that each
additional kilogramme of weight loss was associated with
a 16% reduction in diabetes risk [29], suggesting this de-
gree of weight loss may have conferred some cardiomet-
abolic benefits to the Walking Away group.
Interestingly, changes were not observed in the Walking
Away Plus group, where markers of weight and adiposity
were unchanged compared to control throughout the
trial period. In Walking Away Plus, the mHealth follow-
on support was specifically focused on physical activity
Table 2 Engagement with key components of the intervention
Walking Away (N=450) Walking Away Plus (N=456)
Programme attendance % n % n
Attended initial education session 79.3 357 80.9 369
Attended 12-month refresher session 57.3 258 60.3 275
Attended 24-month refresher session 49.6 223 55.5 253
Attended 36-month refresher session 48.9 220 50.4 230
Attended at least 1 follow-up annual support session 67.6 304 69.7 318
Phone call and text messaging intervention
Registered with text service 77.6 354
Received initial telephone call 69.1 315
Received at least 1 telephone call during the trial 85.1 388
Asked for text messaging service to be stopped 18.9 67
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Table 3 Baseline and change values for objectively assessed physical activity and sedentary behaviour outcomes








N Mean SD N Mean SD N Mean SD Difference 97.5% CI Difference 97.5% CI
Lower Upper Lower Upper
Primary outcome
Total ambulatory activity (steps/day)a
Baseline value 441 6885 3068 427 7264 3009 435 7353 3432
Change at 12
months
374 − 192 1680 319 − 2 2386 324 241 2270 264 − 70 597 547 211 882
Change at 48 months 373 − 385 2217 303 −
312.5
2499 317 − 296 2969 91 − 282 463 121 − 290 532
Secondary outcomes
Censored ambulatory activity (steps/day)a
Baseline value 441 5369.5 2984.0 427 5643 2892 435 5765 3300
Change at 12
months
374 − 192 1633 319 − 7.0 2369 324 228 2247 240 − 90 570 531 201 861
Change at 48
months
373 − 337 2157 303 − 285 2469 317 − 235 2916 66 − 302 433 140 − 263 542
Time spent sedentary (min/day)a
Baseline value 441 557.0 92.9 427 544.0 91.3 435 544.5 97.2
Change at 12
months
374 − 1.5 74.7 319 3.4 73.8 324 2.5 76.6 − 1.9 − 11.1 7.2 − 7.7 − 16.9 1.5
Change at 48
months
373 − 1.4 83.9 303 13.1 81.7 317 23.9 90.3 0.1 − 10.2 10.4 4.7 − 5.7 15.1
Time spent in light physical activity (mins/day)a
Baseline value 441 293.3 80.7 427 310.9 85.7 435 309.0 88.9
Change at 12
months
374 − 7.3 52.3 319 − 10.8 58.8 324 − 7.0 58.8 0.9 − 7.4 9.3 4.4 − 4.1 13.0
Change at 48
months
373 − 14.5 64.5 303 − 15.4 67.7 317 −
21.0
65.2 − 0.1 − 9.8 9.6 − 5.7 − 15.3 4.0
Time spent in moderate-to-vigorous physical activity (min/day)a
Baseline value 441 29.8 24.7 427 31.4 25.7 435 32.1 27.6
Change at 12
months
374 − 1.2 15.2 319 − 0.2 22.2 324 1.7 20.2 1.3 − 1.7 4.3 3.5 0.6 6.5
Change at 48
months
373 − 2.4 19.2 303 − 2.3 23.8 317 − 1.0 24.7 0.5 − 2.8 3.7 1.6 − 1.9 5.0
Time spent sitting or lying down (min/day)b
Baseline value 337 549.3 111.6 333 535.7 113.3 323 545.6 115.3
Change at 12
months
314 − 4.8 84.2 279 10.2 84.2 289 1.6 79.3 4.3 − 10.2 18.9 − 8.4 − 22.9 6.0
Change at 48
months
260 10.2 98.1 213 − 3.7 99.7 211 10.3 94.7 − 15.0 − 33.8 3.8 − 10.6 − 29.9 8.7
Time spent standing (min/day)b
Baseline value 337 288.3 95.1 333 306.7 95.4 323 294.5 100.7
Change at 12
months
314 − 2.8 61.6 279 − 11.1 66.3 289 − 6.8 57.7 − 6.2 − 18.5 6.1 0.3 − 11.8 12.5
Change at 48
months
260 − 12.8 77.5 213 0.8 78.5 211 − 7.4 73.6 12.7 − 2.7 28.1 5.9 − 9.9 21.6
Time spent stepping (mins/day) b
Baseline value 337 106.0 38.1 333 115.3 38.5 323 111.5 43.4
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only, which may have acted to dilute the dietary mes-
sages which were covered in the initial group-based
intervention.
The key strengths of PROPELS are that it is the largest
and longest physical activity trial in those with nondiabetic
hyperglycaemia and it included a multi-ethnic family prac-
tice population and an objective measure of physical activ-
ity. Achieving the predefined target of at least 70% follow-
up for objectively measured physical activity after 48
months is also a strength. However, there are potential
limitations. The length and nature of the trial may have
discouraged some potential participants from taking part,
limiting generalisability. The relatively high levels of am-
bulatory activity and physical activity self-efficacy at base-
line may have limited the effectiveness of the intervention
at promoting further behaviour change. Objective mea-
sures of physical activity reduce error and bias but may
exhibit Hawthorne-like effects (measurement reactivity),
although these are believed to be minimal for MVPA
among adults [30] and are mitigated further by having a
control group. The degree of engagement with WAP (52%
compliance with the per-protocol definition) may have
limited the effectiveness of promoting maintained physical
activity behaviour change. However, there was no evi-
dence that physical activity behaviour change was main-
tained in those that achieved the per-protocol definition
of adherence. The degree of adherence is consistent with
previous implementation studies [31, 32], with data from
the NHS Diabetes Prevention Programme reporting that
approximately 60% of those that attended the initial as-
sessment visit also attended at least one intervention ses-
sion, with just over 10% completing the programme [4].
The PROPELS intervention was predominantly focused
on increasing physical activity volume through walking
behaviour. It is now increasingly recognised that reducing
and breaking sedentary behaviour are also important be-
havioural targets for diabetes prevention and management
that are independent of overall physical activity volume
[33]. Future studies are therefore needed to investigate
whether the integration of reduced sedentary behaviour
Table 3 Baseline and change values for objectively assessed physical activity and sedentary behaviour outcomes (Continued)








N Mean SD N Mean SD N Mean SD Difference 97.5% CI Difference 97.5% CI
Lower Upper Lower Upper
Change at 12
months
314 − 1.4 22.8 279 0.9 29.3 289 4.8 27.3 2.4 − 2.8 7.6 8.5 3.3 13.7
Change at 48
months
260 − 3.7 28.9 213 − 3.2 28.7 211 − 3.7 37.1 2.2 − 4.3 8.6 4.8 − 2.5 12.0
aData derived from waist worn accelerometer
bData derived from thigh worn accelerometer
cData adjusted for wear time at baseline, waking wear time at follow-up, number of valid days at baseline, number of valid days at follow-up, randomisation
stratification variables (centre, ethnicity, sex), and baseline value. Bold indicates significance at p < 0.025
Fig. 2 Change in ambulatory activity in intervention groups compared to control at follow-up
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goals into physical activity interventions more broadly can
increase longer-term effectiveness. Finally, as participants
were only followed up at 12 and 48months, the trajectory
of change between these time points was not evaluated,
making it unclear whether a change in the WAP group
was maintained beyond 12months.
Conclusions
In conclusion, the PROPELS study demonstrated that
combining a pragmatic physical activity intervention
with text messaging and telephone support results in
modest changes in ambulatory activity over 12 months,
but such changes were not maintained at 48 months.
These findings, which are consistent with the wider lit-
erature, suggest individual-level behavioural interven-
tions do not lead to clinically meaningful sustained
increases in physical activity over the longer-term in
high-risk groups.
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